Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 27, Issue 3, Pages 280-286Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2012.12.004
Keywords
-
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV rsk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available